Long-term follow-up of HIV-1 multi-drug-resistant treatment-experienced participants treated with etravirine, raltegravir and boosted darunavir: towards drug-reduced regimen? ANRS CO3 Aquitaine Cohort 2007

Long-term follow-up of HIV-1 multi-drug-resistant treatment-experienced participants treated with etravirine, raltegravir and boosted darunavir: towards drug-reduced regimen? ANRS CO3 Aquitaine Cohort 2007–2018

Published:2023-01 Issue:1 Volume:61 Page:106696
ISSN:0924-8579
Container-title:International Journal of Antimicrobial Agents
language:en
Short-container-title:International Journal of Antimicrobial Agents

Author:

Nyamankolly Elsa,Bellecave Pantxika,Wittkop Linda^ORCID,Le Marec Fabien,Duffau Pierre,Lazaro Estibaliz,Vareil Marc-Olivier,Tumiotto Camille,Hessamfar Mojgan^ORCID,Cazanave Charles,Perrier Adélaïde,Leleux Olivier,Bonnet Fabrice,Neau Didier

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine

Reference49 articles.

1. Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study;Assoumou;J Antimicrob Chemother,2017

2. Blanc A, Bonnet F, Brun-Vezinet F, Costagliola D, Dabis F, Delobel P, et al. Groupe d'experts pour la prise en charge du VIH. 2017. Available at: https://cns.sante.fr/actualites/prise-en-charge-du-vih-recommandations-du-groupe-dexperts/ [last accessed 15 December 2022].

3. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial;Lazzarin;Lancet,2007

4. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial;Madruga;Lancet,2007

5. Raltegravir with optimized background therapy for resistant HIV-1 infection;Steigbigel;N Engl J Med,2008